CN102614470B - 治疗中风后遗症外用中草药组合物 - Google Patents
治疗中风后遗症外用中草药组合物 Download PDFInfo
- Publication number
- CN102614470B CN102614470B CN 201210120837 CN201210120837A CN102614470B CN 102614470 B CN102614470 B CN 102614470B CN 201210120837 CN201210120837 CN 201210120837 CN 201210120837 A CN201210120837 A CN 201210120837A CN 102614470 B CN102614470 B CN 102614470B
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese herbal
- apoplexy
- herbal composition
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 21
- 208000006011 Stroke Diseases 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 241000411851 herbal medicine Species 0.000 claims abstract description 9
- 241001517312 Calanthe Species 0.000 claims abstract description 5
- 210000000582 semen Anatomy 0.000 claims abstract description 5
- 241000283956 Manis Species 0.000 claims description 6
- 241000237636 Pheretima Species 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 241000522620 Scorpio Species 0.000 claims description 5
- 239000009490 scorpio Substances 0.000 claims description 5
- 241000271039 Agkistrodon Species 0.000 claims description 4
- 241000903946 Clematidis Species 0.000 claims description 4
- 241000131808 Scolopendra Species 0.000 claims description 4
- 239000008361 herbal raw material Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 18
- 241000759271 Alangium Species 0.000 abstract 1
- 241000758794 Asarum Species 0.000 abstract 1
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 241000218158 Clematis Species 0.000 abstract 1
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 244000008991 Curcuma longa Species 0.000 abstract 1
- 241001022083 Flemingia Species 0.000 abstract 1
- 241000195954 Lycopodium clavatum Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 241000271897 Viperidae Species 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 230000036407 pain Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 235000003143 Panax notoginseng Nutrition 0.000 description 3
- 241000180649 Panax notoginseng Species 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- SLLMHZXMVHNZOR-UHFFFAOYSA-N Kakuol Chemical compound C1=C(O)C(C(=O)CC)=CC2=C1OCO2 SLLMHZXMVHNZOR-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010050031 Muscle strain Diseases 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000003177 cardiotonic effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000218628 Ginkgo Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000736919 Pelodiscus sinensis Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007180 Sunstroke Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229940023032 activated charcoal Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- -1 glucosides phenols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- BCZFSDNVXODRAJ-JTTNIQEDSA-N lycopodine Chemical compound C1CCN2CCC[C@@H]3[C@H]4C[C@@H](C)C[C@]32[C@H]1C(=O)C4 BCZFSDNVXODRAJ-JTTNIQEDSA-N 0.000 description 1
- BCZFSDNVXODRAJ-ZHMBSYLPSA-N lycopodine Natural products C1CCN2CCC[C@@H]3[C@H]4C[C@H](C)C[C@]32[C@H]1C(=O)C4 BCZFSDNVXODRAJ-ZHMBSYLPSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000009562 momordin Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗中风后遗症外用中草药组合物,各中草药原料按重量配比为:八角枫30、穿山甲10、地龙20、全蝎15、郁金20、青木香30、千斤拨30、伸筋草30、白附子15、生黄芪20、威灵仙30、白花蛇10、蜈蚣10、细辛8、木鳖子15、九子连环草20。它治疗费用低,治疗效果好。
Description
技术领域
本发明涉及一种中药组合物,尤其是指一种治疗中风后遗症外用中草药组合物。
背景技术
中风的病因病机主要是由于阴虚于下,阳亢于上,血随气逆,并走于上,而风、痰火、气、血虚互相影响所致。中风病,属现代医学脑血管病范畴,是一种具有较高发病率及致残率的疾病,是中老年人的常见病,而且,发病年龄有年轻化的趋势。在中风病中,缺血性中风的比例较高,据流行病学调查,脑血管病18%为脑出血,82%为脑梗塞。有关调查资料表明,我国每年中风发病率为115.8/10万,特别是中风病后的智力障碍与肢体致残,已成为严重的社会问题和医学难题。发病后1周内经急救存活的患者中,有73%-86%出现偏瘫,71-77%有行动困难,47%不能独自坐立,44%有体感觉障碍,中风病的致残率很高。中风后遗症严重,因此用中草药治疗中风后遗症开辟一条新的渠道。中国专利曾公开了“一种治疗中风病的中药组合物及其制备方法和质量控制方法”(中国,公开号CN1476891A,公开日2004年2月25日),该组合物主要由栀子150-220重量份、三七总皂苷3-9重量份组成。该中药组合物制备时将栀子用乙醇渗漉,浓缩至清膏,上活性炭柱,得栀子半成品;取栀子半成品用适量注射用水溶解,另取处方量的三七总皂苷,加适量注射用水溶解,滤过,将三七药液与栀子药液混匀,调节pH值,滤膜滤过,热压灭菌制得注射剂。同时还提供了对该组合物进行成分鉴别、含量测定、指纹图谱的质量控制方法。中国专利曾公开了“一种治疗中风病的中药组合物”(中国,公开号CN1486739A,公开日2004年7月7日),该组合物是由水蛭粉、地龙、全蝎、川芎、葛根、银杏叶、羌活、黄精、制首乌、北黄芪、桂枝、红花、当归、天麻、川断、蛇床子原料药制成。治疗中风病及中风后遗症效果显著。
发明内容
本发明的目的在于提供一种治疗中风后遗症外用中草药组合物,治疗费用低,治疗效果好。
为达到上述目的,本发明采取如下的技术方案:一种治疗中风后遗症外用中草药组合物,各中草药原料按重量配比为:八角枫30、穿山甲10、地龙20、全蝎15、郁金20、青木香30、千斤拨30、伸筋草30、白附子15、生黄芪20、威灵仙30、白花蛇10、蜈蚣10、细辛8、木鳖子15、九子连环草20。
本发明是在祖传方剂的基础上,根据临床实践,对患者的用药跟踪观察,不断调整配方,形成上述成方。它治疗费用低,效果好。各中草药易得,用量少,价格低,外敷方便,便于携带保存。
具体实施方式
一种治疗中风后遗症外用中草药组合物,各中草药原料配比为:八角枫30g、穿山甲10g、地龙20g、全蝎15g、郁金20g、青木香30g、千斤拨30g、伸筋草30g、白附子15g、生黄芪20g、威灵仙30g、白花蛇10g、蜈蚣10g、细辛8g、木鳖子15g、九子连环草20g。
各中草药经科学配伍,制成药饼药膏,外敷于患处,充分发挥它们的药效。它们的药理简述如下。
八角枫:八角枫含生物喊、糖苷酚类、氨基酚、有、机酚、强心苻与树脂等,八角枫支根醇提取液能加强催眼药的作用,煎剂或总生物碱均可兴奋呼吸,但当剂量加大时呼吸停止,对正常试验动物可引起血压下降,长期应用可能对肝肾功能产生一定影响。
穿山甲:用于消肿排脓,搜风通络,痈肿疮毒,关节痹痛,麻木拘挛等,穿山甲片的水煎液有明显延长大白鼠及小白鼠凝血时间和降低大白鼠血液黏度的作用,穿山甲片中的环二肤酸能提高小白鼠常压缺氧的耐受能力。此外还有抗炎抑制诱变的作用。
地龙:地龙能清热定惊、通络、平喘、利尿、惊痛抽搐,关节痹痛,肢体麻木,半身不遂,水肿、抗凝血,溶血栓等作用。
全蝎:用于熄风镇痉镇痛、慢性疼痛,攻毒散结,通络止痛,小儿惊风,抽搐痉挛,中风、半身不遂,破伤风,风湿顽痹、偏头痛,抗炎消肿等作用。
郁金:用于行气化瘀、解郁、胸腹胀痛、刺痛,热病神昏癫痛发狂,镇痛、调节免疫功能等作用。
千斤拨:用于祛风湿,强腰膝,用干治疗风湿性关节炎,跌打损伤、腰肌劳损、下肢软弱无力、慢性腰腿疼痛,千斤拨还能治疗慢性肾炎、扁桃体炎等作用。
青木香:用于肝胃气滞所致的胸胁刺痛,脘胀痛,疝气痛,湿热下痢,内伤暑而致的泻痢腹痛,有镇痛消炎作用。
伸筋草:伸筋草水浸剂有解热作用,醇提取液有镇痛作用,能显著延长戊巴比妥纳催眠小鼠的睡眼时间,石松碱对离体大鼠解除小儿痉挛性尿潴留及便秘等。
白附子:在低钙状太下有明显的强心作用,但在正常情况下无强心作用,其镇痛作用较强而且持久,可增加小鼠常压及注射导丙肾上腺素后的耐缺氧时间,因此有抗缺氧作用。此外还镇静及抗炎作用。
生黄芪:用于补气固表,利尿抚毒,排脓,敛疮生肌,气虚乏力、中气不陷,表虚自汗,气虚水肿,痈疽难溃,久溃不敛血虚痿黄,内热消渴等作用。
威灵仙:水提醇沉液对垂体后叶素所致的大鼠心肌缺血有保护作用,酸提取物能松弛肠鼠离体回旸平滑肌,对抗组胺或乙酞胆碱引起的回肠收缩,水煎剂对白鼠疟原虫感染有明显的抑制作用。
白花蛇:对二甲苯所致的小鼠耳廓炎症及大小鼠蛋清性足跖肿胀有阳显的抑制作用,能延长痛反应潜伏期,且不易产生耐受性和习惯性,蛇毒制剂具有抗血栓形成,降低纤维蛋白,血液豁度、血小扳数量,黏附率和聚集的功能。
蜈蚣:可引起家兔小肠先兴奋后抑制,能减少不孕子宫的松弛,减弱子宫的正常收缩,其作用可被肾上腺素所阻抗。此外还有肿瘤、抗惊厥、促进免疫功能、抗真菌、抗炎、镇痛、抗衰老、增强心肌收缩力等作用。
细辛:甲基丁香酚对小鼠有一定的镇痛作用,细辛煎剂能可逆地阻滞蟾蜍坐骨神经的冲动传导,细辛醇浸剂给家兔静脉注射可对抗吗啡所致的呼吸抑制。此处还有抗炎、改善呼吸、抑制平滑肌收缩、强心、抗休克、降温、催眼、抑菌调节血压等作用。
朩鳖子:木鳖子有!降压的作用,但是毒性较大,木鳖子皂苷静脉注射可致大鼠短暂的呼吸兴奋和血压下降,注射于狗动脉能增加其后肢末梢血管的血流量,能抑制离体蛙心,增加乙酰胆碱对豚鼠回肠的兴奋性。此外还有抗炎溶血等作用。
九子连环草:用于舒筋活血,祛风止痛作用,还能治疗风湿性关节炎、类风湿性关节炎肿痛,腰肌劳损,跌打损伤、等作用。
该药治疗患者132例,男姓患者98例,女姓患者34例,重的患者56例,较轻的患者42例,重的患者5个月至7个月可治愈,较轻的患者3个月至4个月可治愈,治愈可达98%例,坚持不住的患者53例,坚持治疗的患者79例。
Claims (1)
1.一种治疗中风后遗症外用中草药组合物,其特征在于各中草药原料按重量配比为:八角枫30、穿山甲10、地龙20、全蝎15、郁金20、青木香30、千斤拨30、伸筋草30、白附子15、生黄芪20、威灵仙30、白花蛇10、蜈蚣10、细辛8、木鳖子15、九子连环草20。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210120837 CN102614470B (zh) | 2012-04-10 | 2012-04-10 | 治疗中风后遗症外用中草药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210120837 CN102614470B (zh) | 2012-04-10 | 2012-04-10 | 治疗中风后遗症外用中草药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102614470A CN102614470A (zh) | 2012-08-01 |
CN102614470B true CN102614470B (zh) | 2013-10-23 |
Family
ID=46554917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210120837 Expired - Fee Related CN102614470B (zh) | 2012-04-10 | 2012-04-10 | 治疗中风后遗症外用中草药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102614470B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103110902B (zh) * | 2013-02-20 | 2014-05-07 | 邱志恒 | 一种治疗中风后抑郁症的中药足浴液 |
CN104001068A (zh) * | 2014-06-11 | 2014-08-27 | 刘光辉 | 一种治疗中风后遗症的中药组合物 |
CN104606503A (zh) * | 2015-02-12 | 2015-05-13 | 蒋文达 | 一种治疗中风后遗症的中药组合物 |
-
2012
- 2012-04-10 CN CN 201210120837 patent/CN102614470B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102614470A (zh) | 2012-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101530566A (zh) | 治疗风湿、类风湿的药物 | |
CN102178800B (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法 | |
CN103386022B (zh) | 一种治疗结核性胸膜炎的中药组合物 | |
CN101134085A (zh) | 治疗中风偏瘫的中药 | |
CN103223118B (zh) | 一种治疗面瘫的中药组合物 | |
CN103432545A (zh) | 一种用于小儿退烧的药物及其制备方法 | |
CN102614470B (zh) | 治疗中风后遗症外用中草药组合物 | |
CN104758690A (zh) | 一种用于术前麻醉的中药制剂及制备方法 | |
CN102626478A (zh) | 治疗陈年腰肌劳损外用中草药组合物 | |
CN102626443B (zh) | 治疗痛风中草药组合物 | |
CN100420454C (zh) | 用于治疗中风病的药物组合物和其制备方法 | |
CN102416145A (zh) | 一种治疗月经失调的中药组合物 | |
CN102357228B (zh) | 一种治疗肝病的中药组合物 | |
CN104435125A (zh) | 一种治疗病毒性肝炎的中药组合物制剂 | |
CN102078559A (zh) | 一种具有补肾健脑功能的中药组合物 | |
CN103479835A (zh) | 一种治疗肝硬化的中药 | |
CN100515450C (zh) | 一种用于治疗痛经的药物及其制备方法 | |
CN103405502B (zh) | 一种治疗偏瘫的药物及其制备方法 | |
CN102755516B (zh) | 抑制艾滋病病毒的中药制剂及其制备方法 | |
CN102940674B (zh) | 治疗前列腺增生的药物组合物 | |
CN102805803B (zh) | 一种治疗类风湿性关节炎的中药 | |
CN103520574B (zh) | 一种治疗慢性肝炎的中药 | |
CN102526511B (zh) | 一种治疗高血压的中药组合物 | |
CN100998720B (zh) | 一种治疗胞宫瘀滞型闭经的内服中药 | |
CN105663785A (zh) | 一种用于治疗偏头痛的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131023 |
|
CF01 | Termination of patent right due to non-payment of annual fee |